The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti HER2 based regimensDESTINY-Breast03
Breast Cancer
Breast Cancer
HER2+
DESTINY-Breast03
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Durvalumab
Gemcitabine and cisplatin
Placebo + gemcitabine and cisplatin
Durvalumab in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer TOPAZ-1
Gastrointestinal Cancers
Biliary tract cancer
-
TOPAZ-1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Trastuzumab deruxtecan
-
Pysician's ChT choice (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel)
Treatment of patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapyDESTINY-Breast04
Breast Cancer
Breast Cancer
HER2-low
DESTINY-Breast04
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Darolutamide
ADT ((androgen deprivation therapy) + docetaxel
ADT + Docetaxel + placebo
For adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapyARASENS
Genitourinary Cancers
Prostate cancer
-
ARASENS
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Cemiplimab
-
Single arm (Phase II)
For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiationR2810-ONC-1423/R2810-ONC-1540
Skin Cancers
Cutaneous Squamous Cell Carcinoma
-
R2810-ONC-1423/R2810-ONC-1540
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Tremelimumab
Durvalumab and platinum-based ChT
Platinum-based ChT
EMA: First-line treatment of tremelimumab in combination with durvalumab and platinum-based chemotherapy (ChT) for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations - FDA: Tremelimumab in combination with durvalumab and platinum-based ChT for adult patients with metastatic NSCLC with no EGFR mutation or ALK genomic tumor aberrations.POSEIDON
Thoracic Malignancies
Non-small-cell Lung Cancer
-
POSEIDON
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Elacestrant
-
Standard-of-care endocrine therapy
Treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitorEMERALD
Breast Cancer
Breast Cancer
ER+ HER2-negative, ESR1-mutated
EMERALD
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Avelumab
-
Single arm (Phase II)
Adult patients with metastatic Merkel cell carcinoma (MCC)JAVELIN Merkel 200 (Part B - treatment-naïve patients)
Skin Cancers
Merkel cell carcinoma
-
JAVELIN Merkel 200 (Part B - treatment-naïve patients)
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Trifluridine/Tipiracil (TAS-102)
Bevacizumab
Trifluridine/Tipiracil (TAS-102)
Treatment of patients with mCRC who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based ChT, anti-VEGF agents and/or anti-EGFR agents SUNLIGHT
Gastrointestinal Cancers
Colorectal Cancer
-
SUNLIGHT
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Cisplatin or carboplatin/5-FU
Cisplatin or carboplatin/5-FU/cetuximab
In combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1KEYNOTE-048
Head and neck cancer
Squamous cell
CPS PD-L1 expression ≥20
KEYNOTE-048
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Cisplatin or carboplatin/5-FU
Cisplatin or carboplatin/5-FU/cetuximab
First-line treatment of patients with metastatic or unresectable, recurrent SCCHNKEYNOTE-048
Head and neck cancer
Squamous cell
-
KEYNOTE-048
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
ADT–docetaxel ± RT
ADT–docetaxel ± RT
De novo mHSPC (ADT with docetaxel population)PEACE-1
Genitourinary Cancers
Prostate cancer
-
PEACE-1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
ADT ± docetaxel ± RT
ADT ± docetaxel ± RT
De novo mHSPC (Overall population)PEACE-1
Genitourinary Cancers
Prostate cancer
-
PEACE-1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Tislelizumab
-
Chemotherapy
Indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapyRATIONALE 302
Gastrointestinal Cancers
Oesophageal Cancer
-
RATIONALE 302
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Dostarlimab
Carboplatin and paclitaxel
Placebo + carboplatin + paclitaxel
Dostarlimab with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability high (MSI H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.RUBY
Gynaecological Malignancies
Endometrial Cancer
dMMR/MSI-H
RUBY
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Cemiplimab
Platinum-based ChT
Placebo
Cemiplimab in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrationsEMPOWER-Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
-
EMPOWER-Lung 3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Erdafitinib
-
ChT (docetaxel or vinflunine)
FDA: For adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy./ EMA: Erdafitinib as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment settingTHOR/BLC3001 cohort 1
Genitourinary Cancers
Urothelial Carcinoma
FGFR3
THOR/BLC3001 cohort 1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Durvalumab
-
Sorafenib
Durvalumab as monotherapy indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)HIMALAYA
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
HIMALAYA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2c
4
Nirogacestat
-
Placebo
Nirogacestat for adult patients with progressing desmoid tumours who require systemic treatment.DeFi
Non-cancerous soft-tissue tumour
Desmoid (fibrous tissue)
-
DeFi
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Tislelizumab
Pemetrexed and platinum‑containing ChT
Pemetrexed and platinum‑containing ChT
Tisleizumab in combination with pemetrexed and platinum‑containing ChT is indicated for the first-line treatment of adult patients with NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have: locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLCRATIONALE 304
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations
RATIONALE 304
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Enfortumab
Pembrolizumab
Platinum-based ChT
FDA: Enfortumab vedotin in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer. EMA: Pembrolizumab, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.EV-302/KN-A39
Genitourinary Cancers
Urothelial Carcinoma
-
EV-302/KN-A39
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Sugemalimab
Platinum-based chemotherapy
Placebo
Sugemalimab for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapyGEMSTONE-302
Thoracic Malignancies
Non-small-cell Lung Cancer
-
GEMSTONE-302
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Durvalumab
Carboplatin, paclitaxel plus Olaparib
Carboplatin, paclitaxel, and placebo (arm A)
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR)DUO-E
Gynaecological Malignancies
Endometrial Cancer
-
DUO-E
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
Carboplatin and paclitaxel
Carboplatin, paclitaxel, and placebo
Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with dMMR)KEYNOTE-868/NRG-GY018
Gynaecological Malignancies
Endometrial Cancer
dMMR
KEYNOTE-868/NRG-GY018
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
Carboplatin and paclitaxel
Carboplatin, paclitaxel, and placebo
Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with pMMR)KEYNOTE-868/NRG-GY018
Gynaecological Malignancies
Endometrial Cancer
-
KEYNOTE-868/NRG-GY018
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Toripalimab
Paclitaxel + cisplatin
Placebo + paclitaxel + cisplatin
Toripalimab, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.JUPITER-06
Gastrointestinal Cancers
Esophageal Squamous Cell Carcinoma
-
JUPITER-06
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Atezolizumab
-
Vinorelbine or gemcitabine (by investigator choice )
Atezolizumab as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapyIPSOS
Thoracic Malignancies
Non-small-cell Lung Cancer
-
IPSOS
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Trastuzumab emtansine (T-DM1)
-
Lapatinib + capecitabine
As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapyEMILIA
Breast Cancer
Breast Cancer
HER2+
EMILIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pertuzumab
Trastuzumab + docetaxel
Trastuzumab + docetaxel + placebo
Treatment of patients with HER2-positive metastatic or locally recurrent unresectable BC who have not received previous anti-HER2 therapy or ChT for metastatic diseaseCLEOPATRA
Breast Cancer
Breast Cancer
HER2+
CLEOPATRA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lapatinib
Trastuzumab
Lapatinib
Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR- metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChTEGF104900
Breast Cancer
Breast Cancer
HER2+ HR-
EGF104900
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.